Hormonal
Testosterone replacement therapy (TRT) improves erectile function and metabolic parameters in hypogonadal diabetic men, but guidelines do not recommend it solely for improving glycemic control.
If you have diabetes and low testosterone, TRT may help your erectile function and energy, but it is not a cure for high blood sugar. Doctors recommend trying lifestyle changes (diet, exercise, weight loss) first. TRT is prescribed individually after weighing risks and benefits, and is not recommended just to lower blood glucose.
Nevertheless, it is strongly recommended to provide similar treatment for ED in hypogonadal men with and without T2DM... current recommendations lean towards an individualised prescription of TRT after careful patient evaluation...
Why this rating
Based on meta-analyses and trials, but guidelines remain cautious due to mixed results on glycemic control and cardiovascular risk debates.
Source
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Giuseppe Defeudis et al. · Diabetes/Metabolism Research and Reviews · 2021
DOI 10.1002/dmrr.3494
More from this paper
- Men with diabetes mellitus have an approximately 3.5-fold higher prevalence of erectile dysfunction compared to men without diabetes, with severity correlating to the duration and complications of the disease.Good
- Erectile dysfunction in diabetic men is strongly associated with cardiovascular disease, often preceding coronary artery disease by 2-5 years, making ED a predictor of cardiac risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →